{"filing":{"accession_number":"0001193125-26-380215","cik":"0002058707","ticker":null,"company_name":"Attovia Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"atto-20260902.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/atto-20260902.htm"},"events":[{"id":31315,"run_id":28728,"accession_number":"0001193125-26-380215","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Q2 2026 financial results for Attovia Therapeutics. The filing explicitly states \"On September 2, 2026, Attovia Therapeutics, Inc. (the \"Company\") issued a press release reporting its financial results for the second quarter ended June 30, 2026\" and furnishes the full press release as Exhibit 99.1. The exhibit includes condensed consolidated balance sheets and statements of operations showing revenue of $0.45 million, R\u0026D expenses of $18.9 million, and net loss of $20.7 million for Q2 2026, along with corporate updates on clinical pipeline progress and the recently completed IPO.","company_name":"Attovia Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34155,"accession_number":"0001193125-26-380215","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Attovia Therapeutics. The filing explicitly states \"On September 2, 2026, Attovia Therapeutics, Inc. (the \"Company\") issued a press release reporting its financial results for the second quarter ended June 30, 2026\" and furnishes the full press release as Exhibit 99.1. The exhibit includes condensed consolidated balance sheets and statements of operations showing revenue of $0.45 million, R\u0026D expenses of $18.9 million, and net loss of $20.7 million for Q2 2026, along with corporate updates on clinical pipeline progress and the recently completed IPO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:19:16.730091+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34155,"accession_number":"0001193125-26-380215","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Attovia Therapeutics. The filing explicitly states \"On September 2, 2026, Attovia Therapeutics, Inc. (the \"Company\") issued a press release reporting its financial results for the second quarter ended June 30, 2026\" and furnishes the full press release as Exhibit 99.1. The exhibit includes condensed consolidated balance sheets and statements of operations showing revenue of $0.45 million, R\u0026D expenses of $18.9 million, and net loss of $20.7 million for Q2 2026, along with corporate updates on clinical pipeline progress and the recently completed IPO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:19:16.730091+00:00","company_name":"Attovia Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-02"}]}